BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) awarded inducement grants on April 10, 2026 under its 2025 Inducement Plan to a new hire from March 2026.

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) awarded inducement grants on April 10, 2026 under its 2025 Inducement Plan to a new hire from March 2026. The company granted non-qualified stock options for 32,675 shares at an exercise price of $8.40 per share, equal to Nasdaq closing price on the grant date.

The options vest 25% on the first anniversary of the employee's start date and then in 36 equal monthly installments, subject to continued service. The grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Argus Apr 14 session

+2.57% close to close Open Argus

Details

News Market Reaction – BBOT

On Apr 14, the first trading day after this news, BBOT closed 2.57% above the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Key Figures

Current price: $8.40 Inducement options: 32,675 shares Par value: $0.0001 per share +5 more

Current price

$8.40

Closing price on April 10, 2026 grant date

Inducement options

32,675 shares

Non-qualified stock options granted under 2025 Inducement Plan

Par value

$0.0001 per share

Par value of BBOT common stock for the option shares

Vesting cliff

25% after 1 year

One-quarter vests on first anniversary of start date

Remaining vesting

36 monthly installments

Balance vests in 36 equal monthly installments thereafter

Price change 24h

-5.14%

Move prior to/around inducement grant disclosure

52-week range

$8.08–$14.87

Current price near 52-week low and well below high

Market cap

$708,690,648

Equity value at latest provided close

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   AACR presentations

   24h Move

   +1.9%

   Announced multiple AACR 2026 presentations for key RAS-pathway oncology programs.

2. Mar 06

   Preclinical publication

   24h Move

   +5.4%

   Cancer Discovery publication showing potent, selective panKRAS inhibitor BBO-11818 data.

3. Mar 05

   Earnings and pipeline

   24h Move

   +5.4%

   Reported 2025 results, $425.5M cash runway into 2028 and progress on three programs.

4. Feb 12

   Conference participation

   24h Move

   -1.5%

   Planned appearances at Oppenheimer and Leerink investor healthcare conferences.

5. Feb 11

   Inducement grants

   24h Move

   -5.2%

   Announced 65,350 inducement stock options granted to new employees under 2025 plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, exercise price, par value, Nasdaq Listing Rule 5635(c)(4), +1 more

5 terms

non-qualified stock options financial

"The employee received non-qualified stock options to purchase 32,675 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"...with an exercise price of $8.40 per share, the closing price of BBOT’s..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

par value financial

"...shares of BBOT common stock, par value $0.0001 per share, with an exercise..."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Nasdaq Listing Rule 5635(c)(4) regulatory

"...with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity incentive plans financial

"Awards were granted outside of BBOT’s stockholder-approved equity incentive plans..."

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on April 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.

The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $8.40 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BBOT announce about inducement grants on April 13, 2026?

BBOT announced inducement option grants for a March 2026 hire under its 2025 Inducement Plan. According to the company, the April 10, 2026 grants totaled options to purchase 32,675 shares at an $8.40 exercise price, approved under Nasdaq rule 5635(c)(4).

How do the BBOT inducement options vest for the employee hired in March 2026?

The options vest 25% after one year, then monthly over three years thereafter. According to the company, vesting is subject to the employee's continued service and consists of 1/4 on the first anniversary and 36 equal monthly installments thereafter.

What is the exercise price and effective date for BBOT's April 10, 2026 grant?

The exercise price is $8.40 per share, the Nasdaq closing price on the effective date. According to the company, the grant effective date was April 10, 2026, matching the reported Nasdaq closing price used for the award.

Why were the awards granted outside BBOT’s stockholder-approved plans?

The awards were issued as material inducements under BBOT’s 2025 Inducement Plan for a new hire. According to the company, grants were made outside existing equity plans and adopted by the board in October 2025 to comply with Nasdaq Listing Rule 5635(c)(4).

Who approved the inducement awards at BBOT and under which Nasdaq rule?

The compensation committee approved the inducement awards under Nasdaq Listing Rule 5635(c)(4). According to the company, the committee, composed solely of independent directors, approved the grants as a material inducement to employment.